This preventive drug could be a 'game changer' in ending the HIV epidemic
In newly released data, lenacapavir, given via a twice-yearly injection, has shown remarkable effectiveness at eliminating HIV transmission during sexual contact. But its cost could be an issue.
Meet Lenacapavir: The drug that could end HIV epidemic
Potential to revolutionize HIV prevention. Ethel Weld, an Assistant Professor of Medicine at Johns Hopkins University School of Medicine, hailed the results as "a thrilling game c
Twice-yearly injectable lenacapavir, an HIV-prevention drug, reduces risk by 96%
Gilead researchers say lenacapavir “has the potential to be one of the most impactful interventions” in the battle against HIV.
Twice-Yearly Injectable Lenacapavir Bests Daily PrEP Tablet for HIV Prevention
Twice-yearly lenacapavir was found to be superior to daily emtricitabine 200mg and tenofovir disoproxil fumarate 300mg.
Twice-yearly injection cuts HIV risk by 96%, but will cost cut access?
It could be a real breakthrough for people at risk for HIV infection: A shot given every six months that reduces their risk by a whopping 96%.
Twice-a-year injection reduced risk of HIV infection by 96%, drug company says — more than daily PrEP pill
A drug currently used to treat HIV has also been found to dramatically reduce the risk of infection, significantly more than the primary option available for pre-exposure prophylaxis or PrEP.
Twice-yearly injection reduced HIV infections by 96 percent, company says
Lenacapavir, a new HIV prevention drug, has proven to dramatically reduce the risk of infection according to data reported from the drugmaker Gilead Sciences, who found two annual injections of the drug reduced HIV infections by 96 percent.
Injectable HIV drug is highly effective, but cost concerns advocates
Clinical trials for the injectable HIV prevention drug lenacapavir have yielded significant results, with the drug proving 89% more effective than daily oral pre-exposure prophylaxis among gay, bisexual and transgender individuals,
GlobalData on MSN4d
Gilead’s lenacapavir: HIV prospects strongest in long-acting combos with Merck’s islatravir
Gilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, ...
STAT2d
Tested in Africa, used in America
The process for translating clinical trial results into action for young women in Africa has been left to our imaginations, ...
ThePrint on MSN2d
Why Indian patients groups are opposing patent requests for blockbuster HIV drug lenacapavir
Granting patents to US firm Gilead Sciences for lenacapavir could hinder global efforts to end AIDS & restrict access to ...
US-based pharma giant Gilead Sciences wants HIV drug Lenacapavir patented
On September 19, 2024, the Indian Patent Office will hear objections filed by Sankalp Rehabilitation Trust against Gilead's ...
Gilead Unveils 'Remarkable Outcomes' From Late-Stage Lenacapavir Study Showing Promise In Preventing HIV Infections
Gilead Sciences' Phase 3 trial results show twice-yearly HIV-1 capsid inhibitor lenacapavir reduced HIV infections by 96%, ...
Hold Rating on Gilead Sciences Amid Lenacapavir’s Promise and Market Uncertainties
Leerink Partners analyst Daina Graybosch has maintained their neutral stance on GILD stock, giving a Hold rating on September 12. “Daina ...